Understanding NK cell biology for harnessing NK cell therapies: targeting cancer and beyond
Gene-engineered immune cell therapies have partially transformed cancer treatment, as exemplified by the use of chimeric antigen receptor (CAR)-T cells in certain hematologic malignancies. However, there are several limitations that need to be addressed to target more cancer types. Natural killer (N...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-07-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1192907/full |
| _version_ | 1827898883784572928 |
|---|---|
| author | Eunju Shin Eunju Shin Seong Ho Bak Seong Ho Bak Taeho Park Taeho Park Jin Woo Kim Jin Woo Kim Suk-Ran Yoon Suk-Ran Yoon Haiyoung Jung Haiyoung Jung Haiyoung Jung Ji-Yoon Noh Ji-Yoon Noh Ji-Yoon Noh |
| author_facet | Eunju Shin Eunju Shin Seong Ho Bak Seong Ho Bak Taeho Park Taeho Park Jin Woo Kim Jin Woo Kim Suk-Ran Yoon Suk-Ran Yoon Haiyoung Jung Haiyoung Jung Haiyoung Jung Ji-Yoon Noh Ji-Yoon Noh Ji-Yoon Noh |
| author_sort | Eunju Shin |
| collection | DOAJ |
| description | Gene-engineered immune cell therapies have partially transformed cancer treatment, as exemplified by the use of chimeric antigen receptor (CAR)-T cells in certain hematologic malignancies. However, there are several limitations that need to be addressed to target more cancer types. Natural killer (NK) cells are a type of innate immune cells that represent a unique biology in cancer immune surveillance. In particular, NK cells obtained from heathy donors can serve as a source for genetically engineered immune cell therapies. Therefore, NK-based therapies, including NK cells, CAR-NK cells, and antibodies that induce antibody-dependent cellular cytotoxicity of NK cells, have emerged. With recent advances in genetic engineering and cell biology techniques, NK cell-based therapies have become promising approaches for a wide range of cancers, viral infections, and senescence. This review provides a brief overview of NK cell characteristics and summarizes diseases that could benefit from NK-based therapies. In addition, we discuss recent preclinical and clinical investigations on the use of adoptive NK cell transfer and agents that can modulate NK cell activity. |
| first_indexed | 2024-03-12T23:09:58Z |
| format | Article |
| id | doaj.art-cc65bd11f0b24bc1bb014c24c5a5c392 |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-03-12T23:09:58Z |
| publishDate | 2023-07-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-cc65bd11f0b24bc1bb014c24c5a5c3922023-07-18T08:20:56ZengFrontiers Media S.A.Frontiers in Immunology1664-32242023-07-011410.3389/fimmu.2023.11929071192907Understanding NK cell biology for harnessing NK cell therapies: targeting cancer and beyondEunju Shin0Eunju Shin1Seong Ho Bak2Seong Ho Bak3Taeho Park4Taeho Park5Jin Woo Kim6Jin Woo Kim7Suk-Ran Yoon8Suk-Ran Yoon9Haiyoung Jung10Haiyoung Jung11Haiyoung Jung12Ji-Yoon Noh13Ji-Yoon Noh14Ji-Yoon Noh15Aging Convergence Research Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon, Republic of KoreaCollege of Pharmacy, Chungnam National University, Daejeon, Republic of KoreaAging Convergence Research Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon, Republic of KoreaDepartment of Functional Genomics, Korea University of Science & Technology (UST), Daejeon, Republic of KoreaAging Convergence Research Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon, Republic of KoreaDepartment of Functional Genomics, Korea University of Science & Technology (UST), Daejeon, Republic of KoreaAging Convergence Research Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon, Republic of KoreaDepartment of Functional Genomics, Korea University of Science & Technology (UST), Daejeon, Republic of KoreaDepartment of Functional Genomics, Korea University of Science & Technology (UST), Daejeon, Republic of KoreaImmunotherapy Research Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon, Republic of KoreaAging Convergence Research Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon, Republic of KoreaDepartment of Functional Genomics, Korea University of Science & Technology (UST), Daejeon, Republic of KoreaImmunotherapy Research Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon, Republic of KoreaAging Convergence Research Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon, Republic of KoreaDepartment of Functional Genomics, Korea University of Science & Technology (UST), Daejeon, Republic of KoreaImmunotherapy Research Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon, Republic of KoreaGene-engineered immune cell therapies have partially transformed cancer treatment, as exemplified by the use of chimeric antigen receptor (CAR)-T cells in certain hematologic malignancies. However, there are several limitations that need to be addressed to target more cancer types. Natural killer (NK) cells are a type of innate immune cells that represent a unique biology in cancer immune surveillance. In particular, NK cells obtained from heathy donors can serve as a source for genetically engineered immune cell therapies. Therefore, NK-based therapies, including NK cells, CAR-NK cells, and antibodies that induce antibody-dependent cellular cytotoxicity of NK cells, have emerged. With recent advances in genetic engineering and cell biology techniques, NK cell-based therapies have become promising approaches for a wide range of cancers, viral infections, and senescence. This review provides a brief overview of NK cell characteristics and summarizes diseases that could benefit from NK-based therapies. In addition, we discuss recent preclinical and clinical investigations on the use of adoptive NK cell transfer and agents that can modulate NK cell activity.https://www.frontiersin.org/articles/10.3389/fimmu.2023.1192907/fullnatural killer cellchimeric antigen receptorimmunotherapycanceragingimmune surveillance |
| spellingShingle | Eunju Shin Eunju Shin Seong Ho Bak Seong Ho Bak Taeho Park Taeho Park Jin Woo Kim Jin Woo Kim Suk-Ran Yoon Suk-Ran Yoon Haiyoung Jung Haiyoung Jung Haiyoung Jung Ji-Yoon Noh Ji-Yoon Noh Ji-Yoon Noh Understanding NK cell biology for harnessing NK cell therapies: targeting cancer and beyond Frontiers in Immunology natural killer cell chimeric antigen receptor immunotherapy cancer aging immune surveillance |
| title | Understanding NK cell biology for harnessing NK cell therapies: targeting cancer and beyond |
| title_full | Understanding NK cell biology for harnessing NK cell therapies: targeting cancer and beyond |
| title_fullStr | Understanding NK cell biology for harnessing NK cell therapies: targeting cancer and beyond |
| title_full_unstemmed | Understanding NK cell biology for harnessing NK cell therapies: targeting cancer and beyond |
| title_short | Understanding NK cell biology for harnessing NK cell therapies: targeting cancer and beyond |
| title_sort | understanding nk cell biology for harnessing nk cell therapies targeting cancer and beyond |
| topic | natural killer cell chimeric antigen receptor immunotherapy cancer aging immune surveillance |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1192907/full |
| work_keys_str_mv | AT eunjushin understandingnkcellbiologyforharnessingnkcelltherapiestargetingcancerandbeyond AT eunjushin understandingnkcellbiologyforharnessingnkcelltherapiestargetingcancerandbeyond AT seonghobak understandingnkcellbiologyforharnessingnkcelltherapiestargetingcancerandbeyond AT seonghobak understandingnkcellbiologyforharnessingnkcelltherapiestargetingcancerandbeyond AT taehopark understandingnkcellbiologyforharnessingnkcelltherapiestargetingcancerandbeyond AT taehopark understandingnkcellbiologyforharnessingnkcelltherapiestargetingcancerandbeyond AT jinwookim understandingnkcellbiologyforharnessingnkcelltherapiestargetingcancerandbeyond AT jinwookim understandingnkcellbiologyforharnessingnkcelltherapiestargetingcancerandbeyond AT sukranyoon understandingnkcellbiologyforharnessingnkcelltherapiestargetingcancerandbeyond AT sukranyoon understandingnkcellbiologyforharnessingnkcelltherapiestargetingcancerandbeyond AT haiyoungjung understandingnkcellbiologyforharnessingnkcelltherapiestargetingcancerandbeyond AT haiyoungjung understandingnkcellbiologyforharnessingnkcelltherapiestargetingcancerandbeyond AT haiyoungjung understandingnkcellbiologyforharnessingnkcelltherapiestargetingcancerandbeyond AT jiyoonnoh understandingnkcellbiologyforharnessingnkcelltherapiestargetingcancerandbeyond AT jiyoonnoh understandingnkcellbiologyforharnessingnkcelltherapiestargetingcancerandbeyond AT jiyoonnoh understandingnkcellbiologyforharnessingnkcelltherapiestargetingcancerandbeyond |